Chosunbiz

Ligachem Biosciences expands ADC pipeline with new NovaRock antibody license

LigaChem Biosciences said on the 24th that it signed a technology licensing agreement with U.S. biotech company NovaRock Biotherapeutics for an antibody targeting a new anticancer target to develop an ...

Radiance Biopharma Showcases First‑in‑Class c‑MET/EGFR Bispecific Nano ADC at Leading Global ADC Conference

Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, ...
Seeking Alpha

SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113

Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline PRAGUE & AMSTERDAM--(BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage ...

IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch

IDEAYA Biosciences (NASDAQ:IDYA) outlined upcoming clinical milestones for its precision oncology pipeline, emphasizing an ...
Nasdaq

Next Cure Highlights Progress Across ADC Pipeline As Company Extends Cash Runway Into 2027

(RTTNews) - Next Cure Inc. (NXTC) outlined steady clinical and operational momentum across its two antibody-drug conjugate programs while reporting a preliminary year-end cash position that supports ...
Seeking Alpha

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin ...
MarketWatch

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- ...
The Manila Times

Akari Therapeutics Participates in Virtual Investor "What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy ...
Morningstar

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...
Benzinga.com

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside – Here’s Why

Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with ...
Business Wire

SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113

PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...
Yahoo Finance

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

TAMPA, Fla. and LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered ...